NCT02897765 - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

May 31, 2020

Conditions

Urinary Bladder CancerBladder TumorsTransitional Cell Carcinoma of the BladderMalignant MelanomaMelanomaSkin CancerCarcinoma, Non-Small-Cell LungLung Cancer

Interventions

BIOLOGICAL

NEO-PV-01

Personal cancer vaccine

BIOLOGICAL

Nivolumab

monoclonal antibody against PD1

OTHER

Adjuvant

immune adjuvant

Trial Locations (9)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan Kettering Cancer Center, New York

63130

Washington University in St. Louis, St Louis

77030

MD Anderson Cancer Center, Houston

90095

UCLA Medical Center, Los Angeles

91010

City of Hope, Duarte

94143

University of California San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Center, Boston